Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.

ABSTRACT:

Background

Time to reimbursement (TTR) of new anticancer medicines differs between countries and contributes to unequal access. We aimed to investigate TTR of new anticancer medicines and explore factors influencing the reimbursement process in seven high-income European countries.

Materials and methods

We carried out a retrospective case study of anticancer medicines with European Union Market Access (EU-MA) and a positive Committee for Medicinal Products for Human Use opinion from 2016 until 2021 with subsequent national reimbursement approval (NRA). The National Health Technology Assessment (HTA) and reimbursement websites of Germany, France, UK, the Netherlands, Belgium, Norway and Switzerland were used to identify TTR, defined as time from EU-MA to NRA. Additionally, we

SUBMITTER: Post HC 

PROVIDER: S-EPMC10163159 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature